SlidesetHIVINTEREST 2017Options for young women: DREAMS, GEMS, Multipurpose prevention technologies, PrEP- Kawango Agot, PhD, MPHView Slideset
SlidesetHIVINTEREST 2017PrEP choices and the PrEP pipeline: injectables, implants, and trial design challenges- Mina Hosseinipour MD, MPHView Slideset
SlidesetHIVINTEREST 2017HIV-positive adolescents most at risk of onwards HIV transmission: quantitative findings from a community-traced sample in South Africa- E. ToskaView Slideset
SlidesetHIVINTEREST 2017Hepatitis B virus infection in HIV-seronegative and HIVseropositive MSM in West Africa: prevalence, associated factors, and acceptability of vaccination (CohMSM ANRS 12324 – Expertise France)- T.T.E. DahView Slideset
SlidesetHIVINTEREST 2017The costs of community based HIV self-test (HIV-ST) kit distribution: results from three (3) district sites in Zimbabwe- C. MangenahView Slideset
SlidesetHIVINTEREST 2017Using human resource and infrastructure costing analysis to determine required investments for scaling up HIV and AIDS services for meeting 90-90-90 prescribed treatment targets- M. MalemaView Slideset
SlidesetHIVINTEREST 2017How can government support scale-up of differentiated care? The Zimbabwe Experience- Clorata GwanzuraView Slideset
SlidesetHIVINTEREST 2017How can people living with HIV create demand for differentiated care?- Gift TrapenceView Slideset
SlidesetHIVINTEREST 2017What does differentiated care look like in Malawi?- Stanley NgomaView Slideset
SlidesetHIVINTEREST 2017Treatment sequencing: second- and third-line ART in the era of integrase inhibitors- Carina CesarView Slideset
SlidesetHIVINTEREST 2017Universal access to all essential medicines – What can be done?- Andrew Hill, MDView Slideset
SlidesetHIVINTEREST 2017Progress in HIV prevention and treatment scale-up in sub-Saharan Africa- Karim AkadiriView Slideset
